2024-514216-27-00招募中1 期
A Phase 1 Study of BGB-B3227 Alone and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors
Beigene Ltd.4 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2024年12月11日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 35
- 试验地点
- 4
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
BeOne Medical Officer
Scientific
BeOne Medicines AG
研究点 (4)
Loading locations...
相似试验
招募中
1 期
A study to test BI 765179 alone and in combination with ezabenlimab in patients with advanced cancer (solid tumors) and BI 765179 in combination with pembrolizumab in patients with advanced head and neck cancer2023-510307-22-00Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.116
进行中（未招募）
1 期
A Study in Healthy Men and Women to Test How BI 3000202 is Taken up and Processed by the BodyNCT07273474Boehringer Ingelheim12
招募中
1 期
A study to test how different doses of BI 3731579 are tolerated by healthy people2024-517209-95-00Boehringer Ingelheim International GmbH40
已完成
1 期
A Phase 1 Study of BMS-986360/CC-90001 Alone and in Combination with Chemotherapy or
Nivolumab in Advanced Solid Tumors2022-500930-27-00Celgene Corp., Celgene Corp.48
招募中
1 期
A study to test whether treatment with BI 770371 in combination with pembrolizumab with or without cetuximab helps people with head and neck cancer compared with pembrolizumab alone2024-517091-38-00Boehringer Ingelheim International GmbH55